Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03805984 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
A Phase 1 study of Lassa Fever, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03805984 is a Phase 1 study of Lassa Fever that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03805984, a Phase 1 study of Lassa Fever, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized and double-blinded within study group, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation using the CELLECTRA® 2000 device in healthy adult volunteers.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INO-4500
- DEVICE CELLECTRA® 2000
Study Locations (1)
Missouri
- The Center for Pharmaceutical Research - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2020-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03805984
The ClinicalTrials.gov registry entry for NCT03805984 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lassa Fever appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03805984 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03805984 about?
NCT03805984 is a clinical study titled "Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers". This is a randomized and double-blinded within study group, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation using the CELLECTRA® 2000 device in healthy adult volunteers.
What is the current status of trial NCT03805984?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2019-05-09. Estimated completion is 2020-10-21.
What conditions does trial NCT03805984 study?
This clinical trial studies the following conditions: Lassa Fever.
What interventions are being tested in trial NCT03805984?
The interventions under investigation include: Placebo (DRUG), INO-4500 (DRUG), CELLECTRA® 2000 (DEVICE).
Who is sponsoring clinical trial NCT03805984?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03805984 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lassa Fever
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.